iTeos Therapeutics (ITOS) Competitors $10.31 -0.04 (-0.39%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$10.25 -0.06 (-0.58%) As of 07:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ITOS vs. SDGR, OCUL, VERA, BHVN, EVO, ETNB, JANX, ANIP, EWTX, and MESOShould you be buying iTeos Therapeutics stock or one of its competitors? The main competitors of iTeos Therapeutics include Schrodinger (SDGR), Ocular Therapeutix (OCUL), Vera Therapeutics (VERA), Biohaven (BHVN), Evotec (EVO), 89BIO (ETNB), Janux Therapeutics (JANX), ANI Pharmaceuticals (ANIP), Edgewise Therapeutics (EWTX), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry. iTeos Therapeutics vs. Its Competitors Schrodinger Ocular Therapeutix Vera Therapeutics Biohaven Evotec 89BIO Janux Therapeutics ANI Pharmaceuticals Edgewise Therapeutics Mesoblast Schrodinger (NASDAQ:SDGR) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends. Do analysts rate SDGR or ITOS? Schrodinger presently has a consensus target price of $32.75, suggesting a potential upside of 60.78%. iTeos Therapeutics has a consensus target price of $15.86, suggesting a potential upside of 53.80%. Given Schrodinger's stronger consensus rating and higher possible upside, analysts clearly believe Schrodinger is more favorable than iTeos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Schrodinger 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75iTeos Therapeutics 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.14 Does the media favor SDGR or ITOS? In the previous week, Schrodinger had 4 more articles in the media than iTeos Therapeutics. MarketBeat recorded 7 mentions for Schrodinger and 3 mentions for iTeos Therapeutics. iTeos Therapeutics' average media sentiment score of 1.14 beat Schrodinger's score of 0.31 indicating that iTeos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Schrodinger 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral iTeos Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals hold more shares of SDGR or ITOS? 79.1% of Schrodinger shares are held by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are held by institutional investors. 8.6% of Schrodinger shares are held by insiders. Comparatively, 12.5% of iTeos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has higher earnings & valuation, SDGR or ITOS? iTeos Therapeutics has lower revenue, but higher earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSchrodinger$207.54M7.20-$187.12M-$2.63-7.75iTeos Therapeutics$35M11.27-$134.41M-$3.04-3.39 Which has more volatility & risk, SDGR or ITOS? Schrodinger has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Is SDGR or ITOS more profitable? iTeos Therapeutics has a net margin of 0.00% compared to Schrodinger's net margin of -83.39%. iTeos Therapeutics' return on equity of -21.37% beat Schrodinger's return on equity.Company Net Margins Return on Equity Return on Assets Schrodinger-83.39% -44.74% -26.29% iTeos Therapeutics N/A -21.37%-18.55% SummaryiTeos Therapeutics beats Schrodinger on 9 of the 16 factors compared between the two stocks. Get iTeos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ITOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITOS vs. The Competition Export to ExcelMetriciTeos TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$396.13M$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-3.3920.2228.5419.58Price / Sales11.27299.17429.2495.01Price / CashN/A43.1536.0257.93Price / Book0.647.568.145.54Net Income-$134.41M-$55.11M$3.24B$257.73M7 Day Performance0.78%3.81%0.18%-0.08%1 Month Performance2.08%11.60%5.96%8.09%1 Year Performance-41.29%-2.11%26.24%13.02% iTeos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITOSiTeos Therapeutics3.301 of 5 stars$10.31-0.4%$15.86+53.8%-37.9%$396.13M$35M-3.3990SDGRSchrodinger1.788 of 5 stars$20.63-2.3%$33.25+61.2%-10.2%$1.55B$207.54M-7.84790Analyst ForecastOCULOcular Therapeutix3.8921 of 5 stars$9.61-0.1%$17.33+80.4%+31.6%$1.53B$63.72M-8.36230VERAVera Therapeutics4.2277 of 5 stars$22.97-4.3%$65.00+183.0%-36.9%$1.53BN/A-7.6640Positive NewsBHVNBiohaven3.3474 of 5 stars$13.81-5.6%$58.46+323.3%-65.5%$1.49BN/A-1.48239News CoverageEVOEvotec1.9839 of 5 stars$4.18-0.5%$5.93+41.9%-13.8%$1.49B$862.40M0.004,827Gap UpETNB89BIO1.8222 of 5 stars$10.22+0.6%$26.43+158.6%+16.8%$1.48BN/A-3.0240JANXJanux Therapeutics2.5345 of 5 stars$23.96-2.0%$95.25+297.5%-40.7%$1.45B$9.34M-17.6230ANIPANI Pharmaceuticals3.7256 of 5 stars$64.91-0.6%$80.13+23.4%+1.2%$1.41B$614.38M-51.11600News CoverageAnalyst RevisionEWTXEdgewise Therapeutics1.4594 of 5 stars$12.61-3.2%$40.00+217.2%-41.5%$1.37BN/A-8.1460MESOMesoblast2.1957 of 5 stars$10.53-1.4%$18.00+70.9%+43.3%$1.36B$5.90M0.0080 Related Companies and Tools Related Companies SDGR Competitors OCUL Competitors VERA Competitors BHVN Competitors EVO Competitors ETNB Competitors JANX Competitors ANIP Competitors EWTX Competitors MESO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ITOS) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iTeos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ITOS Stock Alerts